Hoertel, Nicolas http://orcid.org/0000-0002-7890-1349
Sánchez-Rico, Marina http://orcid.org/0000-0002-1121-8641
Cougoule, Céline
Gulbins, Erich
Kornhuber, Johannes http://orcid.org/0000-0002-8096-3987
Carpinteiro, Alexander
Becker, Katrin Anne
Reiersen, Angela M. http://orcid.org/0000-0003-3203-4590
Lenze, Eric J.
Seftel, David
Lemogne, Cédric http://orcid.org/0000-0002-3487-4721
Limosin, Frédéric
Article History
Received: 30 June 2021
Revised: 26 July 2021
Accepted: 29 July 2021
First Online: 12 August 2021
Competing interests
: NH, MS-R, EG, JK, AC, and FL are inventors on a patent application related to methods of treating COVID-19, filled by Assistance Publique —Hopitaux de Paris in France. NH has received personal fees and nonfinancial support from Lundbeck, outside the submitted work. AMR and EJL are inventors on a patent application related to methods of treating COVID-19, which was filed by Washington University in St. Louis. EJL has received consulting fees from Johnson and Johnson, and Jazz Pharmaceuticals. AMR has received grant or research support from the McDonnell Center for Systems Neuroscience, the McDonnell Center for Cellular and Molecular Neurobiology, and the Taylor Family Institute for Innovative Psychiatric Research. DS is the Chief Medical Officer and CEO of Enable Biosciences, a CLIA certified Federal clinical reference laboratory that performs COVID-19 antibody testing. CL reports personal fees and nonfinancial support from Janssen-Cilag, Lundbeck, Otsuka Pharmaceutical, and Boehringer Ingelheim, outside the submitted work. FL has received speaker and consulting fees from Janssen-Cilag, Euthérapie-Servier, and Lundbeck, outside the submitted work. Other authors declare no competing interests related to this work.
Free to read: This content has been made available to all.